1. Home
  2. GAIN vs ARVN Comparison

GAIN vs ARVN Comparison

Compare GAIN & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gladstone Investment Corporation Business Development Company

GAIN

Gladstone Investment Corporation Business Development Company

HOLD

Current Price

$15.87

Market Cap

651.5M

Sector

Finance

ML Signal

HOLD

Logo Arvinas Inc.

ARVN

Arvinas Inc.

HOLD

Current Price

$8.27

Market Cap

600.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GAIN
ARVN
Founded
2005
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
651.5M
600.2M
IPO Year
2005
2018

Fundamental Metrics

Financial Performance
Metric
GAIN
ARVN
Price
$15.87
$8.27
Analyst Decision
Strong Buy
Buy
Analyst Count
2
19
Target Price
$14.75
$15.05
AVG Volume (30 Days)
150.3K
711.6K
Earning Date
05-12-2026
05-04-2026
Dividend Yield
9.19%
N/A
EPS Growth
20.63
58.84
EPS
0.76
1.70
Revenue
N/A
$262,600,000.00
Revenue This Year
$9.07
N/A
Revenue Next Year
$7.32
N/A
P/E Ratio
$21.12
$4.89
Revenue Growth
N/A
N/A
52 Week Low
$13.14
$6.97
52 Week High
$17.14
$14.22

Technical Indicators

Market Signals
Indicator
GAIN
ARVN
Relative Strength Index (RSI) 39.50 38.71
Support Level $15.78 $7.90
Resistance Level $16.94 $8.40
Average True Range (ATR) 0.28 0.32
MACD -0.05 -0.13
Stochastic Oscillator 17.50 11.88

Price Performance

Historical Comparison
GAIN
ARVN

About GAIN Gladstone Investment Corporation Business Development Company

Gladstone Investment Corp operates as an externally managed, closed-end, non-diversified management investment company. Its objective is to invest in debt and equity securities of established private businesses operating in the U.S., to achieve and grow current income by investing in debt securities of established businesses, and to provide stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses. It focuses on investing in lower-middle-market private businesses.

About ARVN Arvinas Inc.

Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.

Share on Social Networks: